Intravitreal triamcinolone acetonide for serous retinal pigment epithelial detachments in exudative age-related macular degeneration.
BACKGROUND
Due to the high risk of RPE tears PDT is usually not performed in eyes with serous RPE detachments (sRPED). For this reason this subform of exudative AMD was so far untreatable.


METHODS
We report on a prospective uncontrolled observational case series. 20 eyes of 20 patients with subfoveal sRPED demonstrated by OCT were treated between June 2005 and April 2006 with intravitreal triamcinolone acetonide (IVTA). In 15 cases there was a primary sRPED, in 5 cases it had developed after one or more sessions of photodynamic therapy with Visudyne.


RESULTS
There was a trend for better average visual acuity in the group with primary sRPED from 0.73 logMAR (0.19 Snellen equivalent) at baseline (n = 15) to 0.68 logMAR (0.21 Snellen) after one month (n = 15) (p = 0.19) and to 0.60 logMAR (0.25 Snellen) after three months (n = 14) (p = 0.41). The maximal height of sRPED decreased to an average of 35.3 % after one month (n = 15) and increased again to 56.9 % after 3 months (n = 14). One patient was lost to follow-up. In the group of eyes with sRPED after PDT, one eye developed an RPE tear with severe vision loss two weeks after IVTA. In the remaining four eyes average visual acuity improved from 0.90 logMAR (0.13 Snellen) at baseline to 0.73 logMAR (0.19 Snellen) after one month and to 0.80 logMAR (0.16 Snellen) after 3 months. Complete resolution of sRPED was observed in 8/20 eyes (4/5 eyes with sRPED after PDT and 4/15 eyes with primary sRPED).


CONCLUSIONS
IVTA seems to be a therapeutic option in otherwise untreatable eyes with sRPED.
Sutter
F K
FK
Augenklinik, Universitätsspital, Zürich, Switzerland. florian.sutter@usz.ch
Kurz-Levin
M M
MM
Scherrer
M
M
Barthelmes
D
D
Fleischhauer
J C
JC
Helbig
H
H
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D012163:Retinal Detachment / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D014792:Visual Acuity / Q000187:drug effects*; D014822:Vitreous Body
D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide